Stembiosys Inc.
San Antonio, TX
- UEI
- QNQQJ5K2KXG9
- CAGE
- 6QCS8
- Primary NAICS
- 238990 All Other Specialty Trade Contractors
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- X2JKYW2D9EB3
-
- SAM.gov registration date
- Physical address
- 3463 Magic Dr #110, San Antonio, TX 78229, USA
- Website
- stembiosys.com
- Founded
- 2010
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Lab testing service-RFP+ cord blood endothelial progenitors | National Center for Advancing Translational Sciences (NIH) | $15,100 | |
| Endothelial progenitor cells purchase | National Institute on Drug Abuse (NIH) | $66,844 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Link Biosystems Inc. | Irvington, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Curi Bio Inc. | Seattle, WA | 334516 Analytical Laboratory Instrument Manufacturing |
| Fujifilm Cellular Dynamics, Inc. | — | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Trailhead Biosystems Inc. | Beachwood, OH | 325414 Biological Product (except Diagnostic) Manufacturing |
| Asymmetrex, LLC | Boston, MA | — |
About the company
Stembiosys Inc. is a life science tool company specializing in stem and progenitor cells, matrices, media, and other reagents. The company develops proprietary stem cell technologies for the regenerative medicine market. Stembiosys Inc. is registered as a corporate entity and a self-certified small disadvantaged business.
Through prime federal contract awards, Stembiosys Inc. has provided lab testing services and endothelial progenitor cells to the Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences. In 2022, the company received a $15,100 purchase order for "LAB TESTING SERVICE-RFP+ CORD BLOOD ENDOTHELIAL PROGENITORS" with no set-aside designation. In 2021, Stembiosys Inc. was awarded a $66,844 purchase order for "ENDOTHELIAL PROGENITOR CELLS PURCHASE," also with no set-aside used.
Stembiosys Inc. has received a prime federal grant award from the Department of Health and Human Services National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases. The $600,000 project grant, awarded in 2023 and set to be completed in 2025, aims to "DEVELOP A ROBUST NATIVE EXTRACELLULAR MATRIX TO IMPROVE ISLET FUNCTION WITH ATTENUATED IMMUNOGENICITY FOR TRANSPLANTATION." The project involves manufacturing a pancreatic-like extracellular matrix (PI-ECM) using good manufacturing practices (GMP) and comparing its architecture, mechanical properties, and protein composition to the company's current research use only (RUO) version. The goal is to facilitate the recovery of large numbers of high-quality human islets with decreased immunogenicity for potential use in islet transplantation for diabetes treatment.
SBA capabilities narrative
Enabling technologies for cellular and stem cell therapy
Quick answers
Is Stembiosys Inc. registered in SAM.gov?
Yes. Stembiosys Inc.'s SAM.gov registration is active through December 1, 2026.
What is Stembiosys Inc.'s most recent federal award?
Stembiosys Inc.'s most recent federal grant award is Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for… (R43DK135102), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on March 3, 2023.
On GovTribe
See Stembiosys Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors